The evaluation of the effects and satisfaction from the treatment with sildenafil citrate in men with erectile dysfunction after self-administered anabolic steroids
Article published in Urologia Polska 2006/59/4.

authors

Roland Dadej: Katedra i Klinika Urologii i Onkologii Urologicznej Akademii Medycznej w Poznaniu

keywords

penis, erectile dysfunction, doping, anabolic steroids, treatment, sildenafil

summary

Introduction and objectives. There is a growing number of men using anabolic steroids to improve fitness and muscular mass and strength. Usage of potent drugs modifying endocrine functions leads to deep alteration of the vital functions. Erectile dysfunction (ED) is one of the first symptoms. The efficacy and satisfaction from the treatment with sildenafil citrate in men with ED after self administered anabolic steroids was evaluated.

Material and methods. The study group consisted of 31 young men (19-26 years), treated with sildenafil citrate within normal dosage ranges (25-100 mg) - and drug was used according to individual requirements (on-demand basis). Sexual functions were evaluated with questionnaires: International Index of Erectile Function - 5 (IIEF-5), Quality of Life (QoL, 6 points), Quality of Erection Questionnaire (QEQ-7). Results were statistically analyzed.

Results. The significant improvement in the quality of life was observed in the study group. (QoL at the beginning - 4.8+/-1.2 to 1.7+/-0.9). Improvement of the sexual functions was clearly seen (IIEF-5: 15.0+/-3,5 to 20.5+/-2.1, with QEQ 16.9+/-4.1 to 30.4+/-3.3). Satisfaction from the treatment (6 points, first evaluation after dose setting, last after the treatment; 3.5+/-0.8 to 1.6+/-0.6, assuming 1-outstanding, 5-very poor) was assessed as high in the studied population. 74.2% of screened men noted significant and satisfactory improvement of erectile function, with no need of further treatment. Adverse effects were transient and of mild intensity.

Conclusions. Men with ED after self administered anabolic steroids do not need any special treatment modification and respond well to the treatment with standard dose of sildenafil citrate. The treatment significantly improves sexual functions and quality of life.

references

Wagner JC: Enhancement of athletic performance with drugs. An overview. Sports Med 1991, 12 (4), 250-265.
Madea B, Grellner W, Musshoff F, Dettmeyer R: Medico-legal aspects of doping. J Clin Forensic Med 1998, 5 (1), 1-7.
de Baat P, Heijboer MP, van Eijck CH, de Baat C: Health care in sports by a team physician, especially in soccer. Ned Tijdschr Tandheelkd 2005, 112 (4), 130-135.
Hartgens F, Kuipers H: Effects of androgenic-anabolic steroids in athletes. Sports Med 2004, 34 (8), 513-554.
Clarkson PM, Thompson HS: Drugs and sport. Research findings and limitations. Sports Med 1997, 24 (6), 366-384.
Pope HG Jr, Katz DL: Homicide and near-homicide by anabolic steroid users. J Clin Psychiatry 1990, 51 (1), 28-31
Strohmeyer G, Weik C: Liver damage caused by drugs. Z Gastroenterol 1999, 37, 367-378.
Frankle MA, Eichberg R, Zachariah SB: Anabolic androgenic steroids and a stroke in an athlete: case report. Arch Phys Med Rehabil 1988, 69 (8): 632-633.
Bochnia M, Medras M, Pośpiech L, Jaworska M: Poststeroid balance disorder - a case report in a body builder. Int J Sports Med 1999, 20 (6), 407-409.
Sorensen MB, Ingerslev HJ: Azoospermia in 2 body-builders after taking anabolic steroids. Ugeskr Laeger 1995, 20. 157, 1044-1045.
Dadej R: Przypadek uszkodzenia funkcji wydzielniczej przysadki i jąder oraz zaburzeń wzwodu prącia u 23-letniego mężczyzny w wyniku stosowania steroidów anabolicznych w celach niemedycznych. Urol Pol 2005, 4, 298-300.
Ebenbichler CF, Sturm W, Ganzer H et al: Flow-mediated, endothelium-dependent vasodilatation is impaired in male body builders taking anabolic-androgenic steroids. Atherosclerosis 2001, 158 (2), 483-490.
Nilsson S, Spak F, Marklund B, Baigi A, Allebeck P: Attitudes and behaviors with regards to androgenic anabolic steroids among male adolescents in a county of Sweden. Subst Use Misuse 2004, 39 (8), 1183-1197.
Lew-Starowicz Z: Inhibitory fosfodiesterazy typu 5 - podobieństwa i różnice. Seksuol Pol 2003, 1, 2, 79-82.

correspondence